Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines

被引:0
|
作者
R F Rodrigues
L Roque
T Krug
V Leite
机构
[1] Cytogenetic Laboratory,
[2] Centro de Immunologia e Patologia Molecular,undefined
[3] Portuguese Cancer Institute,undefined
[4] R. Professor Lima Basto,undefined
[5] Gene Express,undefined
[6] Lda,undefined
[7] Taguspark,undefined
[8] Valeriano Leite: Molecular Endocrinology Laboratory,undefined
[9] Centro de Immunologia e Patologia Molecular,undefined
[10] Portuguese Cancer Institute,undefined
[11] R. Professor Lima Basto,undefined
来源
British Journal of Cancer | 2007年 / 96卷
关键词
thyroid; CGH; expression; profile;
D O I
暂无
中图分类号
学科分类号
摘要
Information on gene alterations associated to poorly differentiated (PDTC) and anaplastic thyroid carcinomas (ATC) is scarce. Using human cancer cell lines as a tool for gene discovery, we performed a cytogenetic and oligo-array analysis in five new cell lines derived from two PDTC and three ATC. In PDTC we evidenced, as important, the involvement of the MAPK/ERK kinase pathway, and downregulation of a group of suppressor genes that include E-cadherin. In ATC, downregulation of a specific group of oncosuppressor genes was also observed. Our ATC cell lines presented chromosomal markers of gene amplification, and we were able to identify for the first time the nature of the involved amplicon target genes. We found that the main molecular differences between the two cell line types were related to signal transduction pathways, cell adhesion and motility process. TaqMan experiments performed for five amplicon target genes and for two genes, which allowed a clear distinction between ATC and PDTC: CDH13 and PLAU corroborated array results, not only in the cell lines, but also in an additional set of primary 14 PDTC and three ATC. We suggest that our findings may represent new tools for the development of more effective therapies to the hitherto untreatable ATC.
引用
收藏
页码:1237 / 1245
页数:8
相关论文
共 50 条
  • [31] Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer-A New Diagnostic and Therapeutic Target?
    Waechter, Sabine
    Di Fazio, Pietro
    Maurer, Elisabeth
    Manoharan, Jerena
    Keber, Corinna
    Pfestroff, Andreas
    Librizzi, Damiano
    Bartsch, Detlef K.
    Luster, Markus
    Eilsberger, Friederike
    CANCERS, 2021, 13 (22)
  • [32] Anaplastic and poorly differentiated thyroid carcinomas at intervention sites: implications of track seeding and the importance of follow-up monitoring- report of two cases
    Seok, Jungirl
    Kim, Yoo Hyung
    Won, Jae-Kyung
    Hwangbo, Yul
    Park, Seog Yun
    Ryu, Junsun
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2025,
  • [33] Relevance of TERT promoter mutations in poorly differentiated and anaplastic thyroid carcinomas. Association with RAS, BRAF or PIK3CA activating mutations
    Feas-Rodriguez, N.
    Munoz, R.
    Alvarez Gago, T.
    Mateos Otero, J. J.
    Cameselle Tejeiro, J. M.
    Garcia-Rostan, G.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S79 - S79
  • [34] POORLY DIFFERENTIATED THYROID CARCINOMAS WITH PRIMORDIAL CELL COMPONENT - A GROUP OF AGGRESSIVE LESIONS SHARING INSULAR, TRABECULAR, AND SOLID PATTERNS
    PAPOTTI, M
    MICCA, FB
    FAVERO, A
    PALESTINI, N
    BUSSOLATI, G
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1993, 17 (03) : 291 - 301
  • [35] Loss of Function SETD2 Mutations in Poorly Differentiated Metastases from Two Hurthle Cell Carcinomas of the Thyroid
    Pecce, Valeria
    Verrienti, Antonella
    Abballe, Luana
    Carletti, Raffaella
    Grani, Giorgio
    Falcone, Rosa
    Ramundo, Valeria
    Durante, Cosimo
    Di Gioia, Cira
    Russo, Diego
    Filetti, Sebastiano
    Sponziello, Marialuisa
    CANCERS, 2020, 12 (07) : 1 - 15
  • [36] Cell Cycle Deregulation and TP53 and RAS Mutations Are Major Events in Poorly Differentiated and Undifferentiated Thyroid Carcinomas
    Pita, Jaime Miguel
    Figueiredo, Ines Filipa
    Moura, Margarida Maria
    Leite, Valeriano
    Cavaco, Branca Maria
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (03): : E497 - E507
  • [37] Activity of mTOR-Inhibitor Rad001 (everolimus) in differentiated and anaplastic thyroid cancer cell lines
    Behlendorf, T.
    Voigt, W.
    Mueller, T.
    Jordan, K.
    Arnold, D.
    Schmoll, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] DIFFERENTIAL PP60C-SRC ACTIVITY IN WELL AND POORLY DIFFERENTIATED HUMAN COLON CARCINOMAS AND CELL-LINES
    WEBER, TK
    STEELE, G
    SUMMERHAYES, IC
    JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (03): : 815 - 821
  • [39] Proteomic analysis of human thyroid cell lines reveals reduced nuclear localization of Mn-SOD in poorly differentiated thyroid cancer cells
    D. Russo
    A. Bisca
    M. Celano
    F. Talamo
    F. Arturi
    A. Scipioni
    I. Presta
    S. Bulotta
    E. Ferretti
    S. Filetti
    A. Scaloni
    G. Damante
    G. Tell
    Journal of Endocrinological Investigation, 2005, 28 : 137 - 144
  • [40] Proteomic analysis of human thyroid cell lines reveals reduced nuclear localization of Mn-SOD in poorly differentiated thyroid cancer cells
    Russo, D
    Bisca, A
    Celano, M
    Talamo, F
    Arturi, F
    Sciploni, A
    Presta, I
    Bulotta, S
    Ferretti, E
    Filetti, S
    Scaloni, A
    Damante, G
    Tell, G
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2005, 28 (02) : 137 - 144